564 Temporal Outcomes and Factors Predictive of Remission and Relapse After Rituximab Therapy of Pemphigus Vulgaris (PV)

Journal of Investigative Dermatology - United Kingdom
doi 10.1016/j.jid.2019.03.640
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Predictive Factors for Autoimmune Pancreatitis Relapse After 3 Years of Maintenance Therapy

Pancreas
Internal MedicineEndocrinologyHepatologyMetabolismDiabetes
2018English

Rituximab and Short-Course Prednisone as the New Gold Standard for New-Onset Pemphigus Vulgaris and Pemphigus Foliaceus

British Journal of Dermatology
DermatologyMedicine
2017English

Severe Pemphigus Vulgaris Requiring Multiple Rituximab Infusions – A Case Report

Pathology
Forensic MedicinePathology
2020English

Brain Abscess Following Rituximab Infusion in a Patient With Pemphigus Vulgaris

American Journal of Case Reports
Medicine
2015English

Biomarkers for Predicting Clinical Relapse in Refractory Pemphigus Patients Treated With Rituximab

Pathology
Forensic MedicinePathology
2020English

Serum Concentration of Interleukin-6 Is Increased Both in Active and Remission Stages of Pemphigus Vulgaris

Mediators of Inflammation
ImmunologyCell Biology
2008English

Pemphigus Vulgaris

Anais Brasileiros de Dermatologia
Dermatology
2019English

Clinical and Immunological Features of Pemphigus Relapse

British Journal of Dermatology
DermatologyMedicine
2019English

Pemphigus Vulgaris and Pemphigus Foliaceus: Differences in Epidemiology and Mortality

Acta Dermato-Venereologica
DermatologyMedicine
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy